NCT06576037 2026-04-16
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
Phase 1 Recruiting
M.D. Anderson Cancer Center
Byondis B.V.
Jacobio Pharmaceuticals Co., Ltd.
Klus Pharma Inc.
Genmab
University of Chicago
Allist Pharmaceuticals, Inc.
Eucure (Beijing) Biopharma Co., Ltd
Arch Oncology
Athenex, Inc.
Ipsen
Harbour BioMed (Guangzhou) Co. Ltd.
Merck Sharp & Dohme LLC
University of Virginia